Pharmacological Basis of Therapeutics
14th Edition
• Author(s)Laurence Brunton; Bjorn
Knollmann
(Goodman & Gilman–Only | Exam-Ready |
Nursing-Focused)
1. Which statement best describes the historical origin of
many modern drugs?
A. Most drugs were initially synthesized through high-
throughput screening
B. Many drugs originated from empirical use of medicinal plants
C. Drug discovery primarily began with receptor theory
,D. Natural products rarely contributed to early
pharmacotherapy
Correct Answer: B
Rationale: Goodman & Gilman emphasizes that many
foundational drugs originated from traditional and empirical
use of medicinal plants, later refined through scientific
methods.
Citation: Goodman & Gilman, 14th ed., Chapter 1 – Drug
Discovery
2. Which factor most directly led to the transition from
empirical drug use to rational drug design?
A. Advances in pharmacokinetics
B. Discovery of molecular drug targets
C. Development of nursing drug protocols
D. Increased availability of synthetic chemicals
Correct Answer: B
Rationale: Rational drug design became possible once specific
molecular targets (e.g., receptors, enzymes) were identified and
characterized.
Citation: Goodman & Gilman, 14th ed., Chapter 1
,3. In modern drug discovery, what is the primary goal of target
identification?
A. To reduce adverse drug reactions
B. To determine drug dosage
C. To identify a molecular structure whose modulation alters
disease
D. To accelerate regulatory approval
Correct Answer: C
Rationale: Target identification focuses on finding a molecular
entity whose modulation produces a desired therapeutic effect.
Citation: Goodman & Gilman, 14th ed., Chapter 1
4. Which type of molecule is most commonly targeted by
therapeutic drugs?
A. Structural proteins
B. Lipids
C. Receptors and enzymes
D. DNA alone
Correct Answer: C
Rationale: Goodman & Gilman identifies receptors and
enzymes as the most frequent and pharmacologically tractable
drug targets.
Citation: Goodman & Gilman, 14th ed., Chapter 1
,5. What is the primary limitation of high-throughput screening
(HTS)?
A. Inability to identify biologically active compounds
B. High cost and technical complexity
C. Dependence on prior structural knowledge
D. Excessive focus on natural products
Correct Answer: B
Rationale: HTS allows rapid testing of compounds but is
resource-intensive and expensive.
Citation: Goodman & Gilman, 14th ed., Chapter 1
6. Which concept best explains how small chemical changes
can markedly alter drug activity?
A. Pharmacodynamic tolerance
B. Structure–activity relationships (SAR)
C. Bioequivalence
D. Drug–drug interaction
Correct Answer: B
Rationale: SAR describes how variations in chemical structure
influence biological activity, potency, and selectivity.
Citation: Goodman & Gilman, 14th ed., Chapter 1
,7. Computer-aided drug design primarily depends on which
information?
A. Epidemiologic data
B. Patient response variability
C. Three-dimensional target structure
D. Postmarketing surveillance data
Correct Answer: C
Rationale: Structure-based drug design requires knowledge of
the 3D structure of the drug target.
Citation: Goodman & Gilman, 14th ed., Chapter 1
8. Which phase of drug discovery evaluates binding affinity
and functional activity?
A. Lead identification
B. Clinical trials
C. Regulatory review
D. Postmarketing surveillance
Correct Answer: A
Rationale: Lead identification involves selecting compounds
with desirable target binding and biological activity.
Citation: Goodman & Gilman, 14th ed., Chapter 1
9. What is a “lead compound”?
,A. A drug approved for clinical use
B. A compound with optimal safety profile
C. A molecule showing desired biological activity suitable for
optimization
D. A compound identified through clinical trials
Correct Answer: C
Rationale: A lead compound serves as the starting point for
chemical modification and optimization.
Citation: Goodman & Gilman, 14th ed., Chapter 1
10. Which property is most important during lead
optimization?
A. Cost of synthesis
B. Therapeutic index and selectivity
C. Brand recognition
D. Route of administration
Correct Answer: B
Rationale: Lead optimization focuses on improving potency,
selectivity, and safety margins.
Citation: Goodman & Gilman, 14th ed., Chapter 1
11. Which statement about natural products in drug discovery
is accurate?
,A. They are no longer useful in modern pharmacology
B. They often provide complex chemical scaffolds
C. They are easier to synthesize than synthetic drugs
D. They lack pharmacologic specificity
Correct Answer: B
Rationale: Natural products frequently serve as complex
templates for drug development.
Citation: Goodman & Gilman, 14th ed., Chapter 1
12. Why are enzymes considered favorable drug targets?
A. They are abundant in plasma
B. Their active sites are well defined
C. They rarely cause adverse effects
D. They do not vary between tissues
Correct Answer: B
Rationale: Enzymes have defined active sites that allow
selective drug binding.
Citation: Goodman & Gilman, 14th ed., Chapter 1
13. Which factor most influences drug selectivity?
A. Route of elimination
B. Chemical interaction with target binding sites
,C. Patient age
D. Drug formulation
Correct Answer: B
Rationale: Selectivity is determined by how specifically a drug
interacts with its molecular target.
Citation: Goodman & Gilman, 14th ed., Chapter 1
14. Which discipline integrates chemistry, biology, and
computational science in drug discovery?
A. Pharmacovigilance
B. Medicinal chemistry
C. Toxicology
D. Epidemiology
Correct Answer: B
Rationale: Medicinal chemistry integrates multiple scientific
disciplines to design and optimize drugs.
Citation: Goodman & Gilman, 14th ed., Chapter 1
15. What is the primary purpose of preclinical testing?
A. Determine market viability
B. Establish dosing in humans
C. Assess biological activity and toxicity in models
D. Obtain regulatory approval
,Correct Answer: C
Rationale: Preclinical studies evaluate efficacy and safety before
human exposure.
Citation: Goodman & Gilman, 14th ed., Chapter 1
16. Which term describes unintended interactions with non-
target molecules?
A. Therapeutic synergy
B. On-target effects
C. Off-target effects
D. Drug bioavailability
Correct Answer: C
Rationale: Off-target effects contribute to adverse drug
reactions and toxicity.
Citation: Goodman & Gilman, 14th ed., Chapter 1
17. Why is target validation critical before drug development
proceeds?
A. It reduces manufacturing costs
B. It confirms relevance of the target to disease
C. It ensures oral bioavailability
D. It guarantees regulatory approval
Correct Answer: B
, Rationale: Target validation ensures that modulating the target
produces a meaningful therapeutic effect.
Citation: Goodman & Gilman, 14th ed., Chapter 1
18. Which approach identifies drugs based on biological
effects rather than known targets?
A. Structure-based design
B. Target-based screening
C. Phenotypic screening
D. Pharmacokinetic modeling
Correct Answer: C
Rationale: Phenotypic screening evaluates observable biological
effects without prior target identification.
Citation: Goodman & Gilman, 14th ed., Chapter 1
19. What is a key nursing implication of early drug discovery
limitations?
A. Drug safety is guaranteed once marketed
B. Adverse effects may emerge due to incomplete target
specificity
C. Drug interactions are fully predictable
D. Monitoring is unnecessary in early therapy
Correct Answer: B